37.00 +0.07 (0.19%)
Pre-Market: 7:32AM EST
|Bid||36.90 x 4200|
|Ask||37.00 x 600|
|Day's Range||36.73 - 37.07|
|52 Week Range||30.90 - 37.37|
|PE Ratio (TTM)||22.81|
|Forward Dividend & Yield||1.36 (3.68%)|
|1y Target Est||N/A|
With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 3% in the fourth quarter, suggesting some upside for healthcare ETFs.
JNJ stock is currently trading higher than its 50-day moving average of $141.62 and higher than its 200-day moving average of $136.52. Since Johnson & Johnson’s 3Q17 earnings release, JNJ stock has gained ~8.2%. The ongoing restructuring process in its Medical Devices business, new product launches, and its attractive product pipeline are expected by some to further boost investor sentiment and trigger a stock price rise.
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
The soft-drink giant offers a solid quarterly dividend, but these three promising businesses will pay you even more to own their shares.
Wall Street is already off to a hot start in the New Year, with the Dow surging to new heights and tech giants like Amazon.com, Inc. (NASDAQ:AMZN) and Nvidia Corporation (NASDAQ:NVDA) picking up right where they left off. The term “institutional investor” covers a large spectrum of companies and firms, including mutual and pension funds, endowments, private foundations, insurance companies, large investment firms, and more. Investment institutions, which pour hundreds of millions of dollars into different stocks, often employ teams of analysts that perform expensive and highly detailed research before making large stock purchases.